New Platforms for Cancer Treatment—Emerging Advances
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmaceutical Technology".
Deadline for manuscript submissions: 25 July 2025 | Viewed by 880
Special Issue Editors
Interests: nonclinical animal models; in vitro activity; experimental chemotherapy; experimental drugs; nanoformulations; cardiotoxicity; neglected diseases and cancer treatment
Special Issues, Collections and Topics in MDPI journals
Interests: polymers; polymers synthesis; biodegradable and decorated polymeric nanocarriers; parasitic diseases and cancer treatment
Special Issues, Collections and Topics in MDPI journals
Interests: pre-clinical mice models; cytotoxicity; efficacy; experimental chemotherapy; cardiotoxicity
Special Issues, Collections and Topics in MDPI journals
Interests: polymeric nanoparticles; biodistribution; oral lipid-based nanosystems; efficacy; biodistribution; pharmaceutical nanotechnology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The aim of this Special Issue, “New Platforms for Cancer Treatment—Emerging Advances”, is to gather high-quality papers in the field and address pharmaceutical strategies focused on cancer treatment. The alarming rise of cancer cases has become a significant public health concern in recent decades. According to the WHO, ten million people died from cancer alone in 2020, regardless of age or social status. Cancer treatment encompasses various approaches, including surgery, radiotherapy, and conventional chemotherapy, often used in drug combinations. Adverse effects are commonly manifested acutely and chronically.
Nanotechnology has emerged as a more selective option for cancer treatment. It offers targeted therapy, biodistribution, and reduced toxicity. Another strategy for advancing cancer treatment is based on gene therapy, including DNA microRNAs, oncolytic virotherapy, and gene-directed enzyme pro-drug deliveries. Efforts to discover new active molecules or novel combinations continue as a strong branch of cancer treatment novelty. Photodynamic (PDT) and photothermal (PTT) cancer therapies are emerging as new options for the counterpart mutilation of organs and tissues. Monoclonal antibodies in cancer treatment represent a great breakthrough in personalized cancer treatment. These antibodies have been used to target nanostructures loaded with different drugs to tumoral areas in the human body with success.
We encourage researchers from the pharmaceutical and health science disciplines to contribute original and review manuscripts highlighting the latest developments in this field. We welcome manuscripts covering in vitro and in vivo screenings and pre-clinical studies with diverse applications to cancer treatment.
The scope of this Special Issue includes the following:
- Novel drugs or active compounds for cancer treatment;
- Nanostructures applied to cancer treatment;
- Use of photodynamics and photothermal agents in nanotheranostics;
- Targeting approaches to improve selectivity in cancer;
- Biopharmaceutical studies of antitumoral drugs associated with nanodevices;
- Reviews of current and up-to-date research in cancer treatment and new strategies.
Dr. Fernanda Karoline Vieira da Silva Torchelsen
Dr. Maria Alice de Oliveira
Dr. Renata Tupinambá Branquinho
Prof. Dr. Vanessa Carla Furtado Mosqueira
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer treatment
- emerging advances
- nanotechnology
- nanotheranostics
- novel drugs
- nanostructures
- pre-clinical studies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
